Finch Therapeutics Group, Inc.
FNCH
$13.45
-$0.55-3.93%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -- | -- |
| Cost of Revenue | -- | -- | -100.00% | -- | -98.54% |
| Gross Profit | -- | -- | 100.00% | -- | 98.50% |
| SG&A Expenses | -31.18% | -46.30% | -48.22% | -61.03% | 8.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.72% | -68.92% | -77.27% | -82.58% | -58.89% |
| Operating Income | 32.72% | 68.71% | 77.26% | 82.47% | 58.21% |
| Income Before Tax | 30.45% | 94.11% | 88.74% | 94.02% | 69.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.45% | 93.78% | 88.74% | 94.02% | 69.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.45% | 93.78% | 88.74% | 94.02% | 69.38% |
| EBIT | 32.72% | 68.71% | 77.26% | 82.47% | 58.21% |
| EBITDA | 32.78% | 66.17% | 75.82% | 81.49% | 55.69% |
| EPS Basic | 30.49% | 93.79% | 88.80% | 94.07% | 69.74% |
| Normalized Basic EPS | 30.01% | 74.48% | 83.21% | 88.94% | 68.69% |
| EPS Diluted | 30.49% | 93.79% | 88.80% | 94.07% | 69.74% |
| Normalized Diluted EPS | 30.01% | 74.48% | 83.21% | 88.94% | 68.69% |
| Average Basic Shares Outstanding | 0.06% | 0.18% | 0.50% | 0.89% | 1.19% |
| Average Diluted Shares Outstanding | 0.06% | 0.18% | 0.50% | 0.89% | 1.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
